Relationship of BMPR2 Mutations to Vasoreactivity in Pulmonary Arterial Hypertension

Background— Vasoreactivity tests are fundamental in evaluating pulmonary arterial hypertension (PAH). Mutations of the transforming growth factor-&bgr; type II receptor gene, BMPR2, predispose to the development of pulmonary hypertension and may alter the response to vasodilators. Previous investigations have not examined the relationship of BMPR2 mutations to vasoreactivity. Methods and Results— We identified 133 consecutive unrelated patients with either idiopathic or familial PAH. Sixty-six patients were excluded because we lacked either DNA samples (n=18) or complete data from a vasoreactivity test (n=48). The remaining 67 patients were screened for BMPR2 DNA sequence variations, and specific variations were confirmed by gene sequencing. The vasoreactivity of patients with nonsynonymous BMPR2 variations was compared with that of patients without nonsynonymous BMPR2 variations. We found nonsynonymous BMPR2 variations in 27 of 67 patients with idiopathic (n=16 of 52) or familial (n=11 of 15) PAH. Vasoreactivity was identified in 3.7% of 27 patients with nonsynonymous BMPR2 variations and in 35% of 40 patients without nonsynonymous BMPR2 variations (P=0.003). Five of the 27 nonsynonymous variations occur commonly in healthy individuals. None of the remaining 22 patients with BMPR2 variations demonstrated vasoreactivity, and the analysis remained unchanged when we assumed that nonsynonymous BMPR2 variations were present in all 15 patients with familial PAH. Conclusions— Patients with familial or idiopathic PAH and nonsynonymous BMPR2 variations are unlikely to demonstrate vasoreactivity. Further trials are required to determine whether long-term therapy can be directed by tests for BMPR2 variations.

[1]  M. Humbert,et al.  Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension , 2005, Circulation.

[2]  J. Cogan,et al.  Gross BMPR2 gene rearrangements constitute a new cause for primary pulmonary hypertension , 2005, Genetics in Medicine.

[3]  R. Ewert,et al.  Low frequency of BMPR2 mutations in a German cohort of patients with sporadic idiopathic pulmonary arterial hypertension , 2004, Journal of Medical Genetics.

[4]  Carl T Wittwer,et al.  Sensitivity and specificity of single-nucleotide polymorphism scanning by high-resolution melting analysis. , 2004, Clinical chemistry.

[5]  D. Mccrory,et al.  Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. , 2004, Chest.

[6]  W. Seeger,et al.  Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.

[7]  J. Knowles,et al.  Genetic basis of pulmonary arterial hypertension: current understanding and future directions. , 2004, Journal of the American College of Cardiology.

[8]  N. Longo,et al.  Rapid, comprehensive screening of the human medium chain acyl-CoA dehydrogenase gene. , 2004, Molecular genetics and metabolism.

[9]  T. Morisaki,et al.  BMPR2 mutations found in Japanese patients with familial and sporadic primary pulmonary hypertension , 2004, Human mutation.

[10]  D. Mccrory,et al.  Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. , 2004, Chest.

[11]  Toshihiro Tanaka.  The International HapMap Project , 2003, Nature.

[12]  E. Stanley,et al.  Direct signaling by the BMP type II receptor via the cytoskeletal regulator LIMK1 , 2003, The Journal of cell biology.

[13]  P. Tam.  The International HapMap Consortium. The International HapMap Project (Co-PI of Hong Kong Centre which responsible for 2.5% of genome) , 2003 .

[14]  R. Speich,et al.  Clinical classification of pulmonary hypertension. , 2004, Journal of the American College of Cardiology.

[15]  R. Barst,et al.  Pulmonary vasoreactivity in PPH. , 2001, Journal of the American College of Cardiology.

[16]  S. Antonarakis,et al.  Nomenclature for the description of human sequence variations , 2001, Human Genetics.

[17]  M. Humbert,et al.  BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. , 2001, American journal of human genetics.

[18]  M. Humbert,et al.  Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-β family , 2000, Journal of medical genetics.

[19]  S. Hodge,et al.  Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. , 2000, American journal of human genetics.

[20]  R. Trembath,et al.  Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension , 2000, Nature Genetics.

[21]  G. Maislin,et al.  Vasodilator therapy for primary pulmonary hypertension in children. , 1999, Circulation.

[22]  M. Rubenfire,et al.  Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine. , 1998, Journal of the American College of Cardiology.

[23]  M. Humbert,et al.  Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. , 1998, The European respiratory journal.

[24]  A. Denjean,et al.  Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. , 1995, American journal of respiratory and critical care medicine.

[25]  B. Groves,et al.  CORRELATION OF ACUTE PROSTACYCLIN RESPONSE IN PRIMARY (UNEXPLAINED) PULMONARY HYPERTENSION WITH EFFICACY OF TREATMENT WITH CALCIUM CHANNEL BLOCKERS AND SURVIVAL , 1993 .

[26]  E. K. Weir,et al.  Ion Flux in Pulmonary Vascular Control , 1993, NATO ASI Series.

[27]  S. Rich,et al.  The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. , 1992, The New England journal of medicine.

[28]  B. Groves,et al.  The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. , 1989, The American review of respiratory disease.

[29]  R. Virmani,et al.  Heterogeneity of pathologic lesions in familial primary pulmonary hypertension. , 1988, The American review of respiratory disease.

[30]  D. Buff.  Primary pulmonary hypertension. , 1987, Annals of internal medicine.

[31]  P. Wood.  PULMONARY HYPERTENSION WITH SPECIAL REFERENCE TO THE VASOCONSTRICTIVE FACTOR* , 1958, British heart journal.

[32]  D. Dresdale,et al.  Recent studies in primary pulmonary hypertension, including pharmacodynamic observations on pulmonary vascular resistance. , 1954, Bulletin of the New York Academy of Medicine.

[33]  D. Dresdale,et al.  Primary pulmonary hypertension. I. Clinical and hemodynamic study. , 1951, The American journal of medicine.